{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:39:51Z","timestamp":1793659191843,"version":"4.5.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Elevated BMI in Hidradenitis Suppurativa is associated with decreased response to Adalimumab therapy. BMI is proposed to segregate distinct disease subtypes. It remains unresolved whether a threshold BMI exists above which increased dosages may provide clinical benefit. Individual patient data from 578 PIONEER Phase 3 participants were analyzed. Descriptive, multivariable regression analysis and receiver operating characteristic (ROC) curves were calculated to assess the relationship between BMI and clinical outcome measures using R v3.5.3. Participants in the overweight and obese BMI category had reduced odds (58 and 67%, respectively) of achieving HiSCR [OR = 0.42 (95%CI \u22120.19, 0.91) <jats:italic>p<\/jats:italic> = 0.03], [OR = 0.33 (95%CI 0.16, 0.67) <jats:italic>p<\/jats:italic> = 0.002] compared to participants with BMI &amp;lt; 25. Reduction in AN count and IHS4 score was not significantly associated. ROC analysis did not reveal any cut off value predictive of treatment outcome. No correlation between BMI and baseline disease activity or covariate interactions were identified. These findings suggest BMI is a significant covariate in the setting of lower baseline disease activity, supporting the concept of disease heterogeneity and differential therapeutic response to Adalimumab.<\/jats:p>","DOI":"10.3389\/fmed.2021.603281","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T04:23:36Z","timestamp":1624335816000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa"],"prefix":"10.3389","volume":"8","author":[{"given":"John W.","family":"Frew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. S.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"552","DOI":"10.2340\/00015555-1800","article-title":"The influence of body weight on the prevalence and severity of hidradenitis suppurativa","volume":"94","author":"Kromann","year":"2014","journal-title":"Acta Derm Venerol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/bjd.13122","article-title":"Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities","volume":"171","author":"Crowley","year":"2014","journal-title":"Br J Dermatol"},{"key":"B4","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/jamadermatol.2017.0432","article-title":"Interventions for hidradenitis suppurativa: updated summary of an original cochrane review","volume":"153","author":"Ingram","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jaad.2019.05.022","article-title":"Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa","volume":"81","author":"Ashley","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the hidradenitis suppurativa clinical response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","article-title":"Clinical response rates, placebo response rates and significant associated covariates are dependent upon choice of outcome measure in hidradenitis suppurativa. A post-hoc analysis of PIONEER 1 and PIONEER 2 individual patient data","volume":"82","author":"Frew","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jdv.14599","article-title":"Low and high body mass index in hidradenitis suppurativa patients-different subtypes?","volume":"32","author":"Theut Riis","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(16)30054-X","article-title":"Trends in adult body-mass index in 200 countries from 1975-2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"B12","unstructured":"R: A Language and Environment for Statistical Computing2017"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.jaad.2015.07.047","article-title":"New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes","volume":"73","author":"Van der Zee","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.02.742","article-title":"In depth analysis of the hidradenitis suppurativa proteome identified distinct inflammatory subtypes","author":"Navrazhina","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"A report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the obesity society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000447716","article-title":"South Italy: a provileged perspective to understand the relationship between hidradenitis suppurativa and overweight\/obesity","volume":"2","author":"Fabbrocini","year":"2016","journal-title":"Skin Appendage Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/jid.2012.255","article-title":"Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted county, Minnesota","volume":"133","author":"Vazquez","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1016\/j.jid.2020.04.011","article-title":"Lipidomic profiling of hidradenitis suppurativa skin lesions reveals lipoxygenase pathway dysregulation and accumulation of pro-inflammatory leukotriene B4","volume":"140","author":"Penno","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbalip.2018.12.014","article-title":"Lipidomic profiling reveals early-stage metabolic dysfunction in overweight or obese humans","volume":"1864","author":"Mousa","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"B20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12788\/j.sder.2017.017","article-title":"Pathophysiology of hidradenitis suppurativa","volume":"36","author":"Hoffman","year":"2017","journal-title":"Semin Cutan Med Surg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jdcr.2017.06.008","article-title":"Remission of hidradenitis suppurativa after bariatric surgery","volume":"3","author":"Gallagher","year":"2017","journal-title":"JAAD Case Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/ced.12269","article-title":"Rapid resolution of hidradenitis suppurativa after bariatric surgical intervention","volume":"39","author":"Thomas","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/jdv.13059","article-title":"Resolution of hidradenitis suppurativa after weight loss by dietary measures, especially on frictional locations","volume":"30","author":"Boer","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/jid.2012.476","article-title":"Phenotypic heterogeneity in hidradenitis suppurativa (acne inversa): classification is an essential step toward personalized therapy","volume":"133","author":"Ingram","year":"2013","journal-title":"J Invest Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.603281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T04:23:41Z","timestamp":1624335821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.603281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":24,"alternative-id":["10.3389\/fmed.2021.603281"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.603281","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"article-number":"603281"}}